~~<i id='76B87FC84E'><strike id='76B87FC84E'><tt id='76B87FC84E'><pre id='76B87FC84E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：comprehensive 2025-10-01 21:40:07 - browse：5517

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： India sets sights on home

focus

hotspot

entertainment

hotspot

leisure time

AdobeThisarticleisadaptedfromthe2023editionofSTAT’sannualreport,“Rankingbiotech’stopventurecapitalfi

WSS

Stanford updates investigation of president’s past research

India sets sights on home

'Reaching a detente': STAT's Helen Branswell on covering Covid

India sets sights on home

Researchers separate signal from noise in heart wearable data

Lindsay Lohan welcomes 1st child with husband Bader Shammas

entertainment

comprehensive

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Man who had jail sentence commuted by Trump arrested again

Apple is now the first public company to be valued at $3 trillion

Couple fighting to bring baby home from Mexico are finally reunited

Jerome Adams on the need for new antivirals for Covid

Stanford updates investigation of president’s past research

Medical leaders decry Supreme Court decision on affirmative action

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

The high cost of giving birth even with insurance

Couple fighting to bring baby home from Mexico are finally reunited

focus

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Researchers separate signal from noise in heart wearable data

Ebola public health emergency is over, WHO declares

TikTok cracks down on users posting about weight loss drugs

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Stanford updates investigation of president’s past research

hotspot

entertainment

hotspot

leisure time